Biomotion Sciences Ordinary Shares (SLXN) is a Healthcare · Biotechnology company listed on NASDAQ. Price $0.44 (+14.61%), Market cap $0.00B, 52-week low–high $0.27 ~ $14.94.
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. Silexion Therapeutics Corp has collaboration with Evonik Corporat
Financial statements, price targets, institutional (13F) holdings and related news for Biomotion Sciences Ordinary Shares are updated in real time on BlackAll Trade.
Biomotion Sciences Ordinary Shares trades at $0.44 (+14.61%). Real-time quotes and charts are available on BlackAll Trade.
Biomotion Sciences Ordinary Shares has a market cap of about $0.00B.
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in